Vertex Pharmaceuticals Incorporated VRTX
547.41 USD -3.46 (-0.63%)
Nov 10, 2026, 9:32 AM EST
544.18 Day range 550.32
421.03 52-week range 558.88
- YTD
- +20.75%
- 1 year
- +29.96%
News
defenseworld.net Vertex Pharmaceuticals Incorporated $VRTX Stock Purchased by Allspring Global Investments Holdings LLC Allspring Global Investments Holdings LLC raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 11.7% during the undefined quarter, according to the company in its most…
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
defenseworld.net Associated Banc Corp Purchases 5,962 Shares of Vertex Pharmaceuticals Incorporated $VRTX Associated Banc Corp acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and…
benzinga.com Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $626 Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $617 to $626.
benzinga.com Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer...' Drugmaker executives doubt AI will cure disease soon, saying biology is too complicated.
defenseworld.net Vertex Pharmaceuticals Incorporated $VRTX Stock Sold by AIA Group Ltd AIA Group Ltd reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 23.8% in the undefined quarter, according to its most recent disclosure with the Securities and…
fxempire.com Vertex Pharmaceuticals Thrives on Higher Sales and Guidance VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.
defenseworld.net Aware Super Pty Ltd as trustee of Aware Super Acquires 11,017 Shares of Vertex Pharmaceuticals Incorporated $VRTX Aware Super Pty Ltd as trustee of Aware Super boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 121.9% in the undefined quarter, according to the company in its…
benzinga.com Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $725 Goldman Sachs analyst Salveen Richter maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $654 to $725.
benzinga.com Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $660 Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and lowers the price target from $665 to $660.- benzinga.com Scotiabank Maintains Sector Outperform on Vertex Pharmaceuticals, Raises Price Target to $660 Scotiabank analyst Louise Chen maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Outperform and raises the price target from $558 to $660.
zacks.com CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.- benzinga.com UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $640 UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $615 to $640.
zacks.com VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.- benzinga.com TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $575 TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $550 to $575.
benzinga.com Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $650 Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $550 to $650.- benzinga.com RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $600 RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $576 to $600.
benzinga.com Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for TEM, TWLO, UPWK, MRSH and PLTR; cut MRVL and AAPL targets, with upgrades for TWLO and MRSH.
benzinga.com Stock Market Today: S&P 500, Nasdaq 100, Dow Jones Futures Mixed as Trump Touts Iran Settlement Hopes — AAPL, PLTR, AMD in Focus (UPDATED) U.S. stocks were mixed on Tuesday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures moved in different directions.
benzinga.com Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported mixed results for the third quarter on Monday.
benzinga.com Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results Vertex missed Q3 EPS estimates but beat sales, raised FY2026 guidance, and shares rose 2.7% as analysts lifted price targets.- benzinga.com Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $563 Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $500 to $563.
- benzinga.com Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $619 Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $595 to $619.
benzinga.com Vertex Pharmaceuticals Q3 2026 Earnings Call Transcript Vertex Pharmaceuticals (NASDAQ:VRTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Vertex Pharmaceuticals Q3 Adj. EPS $4.76 Misses $4.82 Estimate, Sales $3.441B Beat $3.417B Estimate Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.76 per share which missed the analyst consensus estimate of $4.82 by 1.24 percent. This is a 0.83 percent decrease over earnings…
benzinga.com Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $13.100B-$13.200B to $13.150B-$13.250B vs $13.245B Est Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $13.100 billion-$13.200 billion to $13.150 billion-$13.250 billion vs $13.245 billion estimate.
benzinga.com Dow Rises 1%, Oil Sinks 7% on Iran Peace Hopes: Stock Market Today Oil tumbles on renewed U.S.-Iran diplomacy, pulling Treasury yields lower and lifting the Dow, airlines and Amazon while energy stocks lag.
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
benzinga.com Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 4.68% on an annualized basis producing an average annual return of 13.63%. Currently, Vertex Pharmaceuticals…- benzinga.com Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Nephropathy Published In The New England Journal Of Medicine; Vertex’s Povetacicept Shows 49.8% Greater Proteinuria Reduction vs. Placebo In Phase 3 IgAN Trial; FDA Decision Expected November 30 - Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN…
- benzinga.com Vertex Presents Study Reporting ALYFTREK Data Shows Pancreatic Function Recovery In Some Children Ages 2–5 With Cystic Fibrosis - Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also…
benzinga.com If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 10.96% on an annualized basis producing an average annual return of 23.3%. Currently, Vertex Pharmaceuticals…- benzinga.com RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $576 RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $570 to $576.
benzinga.com Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.
benzinga.com $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.27% on an annualized basis producing an average annual return of 19.81%. Currently, Vertex Pharmaceuticals…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday Analysts raised targets for Vertex and Okta, while cutting targets for McDonald’s, AutoZone, Vaxcyte and Camping World.- benzinga.com UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615 UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.
benzinga.com Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.- benzinga.com Vertex Pharmaceuticals Announces Results From Phase 2b AMPLIFIED Study Of Inaxaplin In People With Kidney Disease And Type-2 Diabetes; Treatment With Inaxaplin Led To Reduction In Urine Albumin To Creatinine Ratio Of -42.7% At Week 13 Compared To Baseline; Inaxaplin Was Generally Safe And Well Tolerated In Both Cohorts Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.In this study, inaxaplin was evaluated as…
benzinga.com Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals…- benzinga.com Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.
- benzinga.com If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals…
benzinga.com Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’ CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Vertex (NASDAQ: VRTX) and Brown recommended Uber (NYSE: UBER).- benzinga.com $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals…
- benzinga.com Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565 Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.
- benzinga.com Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617 Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.
- benzinga.com TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550 TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.
benzinga.com Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595 Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.- benzinga.com Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.